Brokerages Anticipate Insulet Co. (NASDAQ:PODD) to Post $0.04 Earnings Per Share

Share on StockTwits

Wall Street brokerages predict that Insulet Co. (NASDAQ:PODD) will post earnings per share (EPS) of $0.04 for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Insulet’s earnings, with estimates ranging from ($0.01) to $0.09. Insulet reported earnings of $0.03 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm is scheduled to announce its next earnings report on Thursday, November 7th.

On average, analysts expect that Insulet will report full year earnings of $0.25 per share for the current year, with EPS estimates ranging from $0.17 to $0.39. For the next financial year, analysts forecast that the company will report earnings of $0.85 per share, with EPS estimates ranging from $0.37 to $1.37. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Monday, August 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). Insulet had a net margin of 2.66% and a return on equity of 7.85%. The business had revenue of $177.10 million during the quarter, compared to the consensus estimate of $163.63 million. During the same quarter in the prior year, the firm posted ($0.03) EPS. The company’s revenue for the quarter was up 42.5% compared to the same quarter last year.

Several equities research analysts have recently commented on PODD shares. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Jefferies Financial Group boosted their price target on shares of Insulet from $105.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. JPMorgan Chase & Co. upgraded shares of Insulet from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $120.00 to $155.00 in a report on Tuesday, August 6th. BTIG Research boosted their price target on shares of Insulet to $140.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Finally, BMO Capital Markets boosted their price target on shares of Insulet from $130.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $131.71.

Shares of NASDAQ:PODD traded up $3.67 during trading hours on Friday, hitting $156.26. The company’s stock had a trading volume of 20,854 shares, compared to its average volume of 1,167,662. Insulet has a 52 week low of $70.80 and a 52 week high of $168.00. The company has a debt-to-equity ratio of 2.43, a current ratio of 4.72 and a quick ratio of 3.91. The company has a market capitalization of $8.74 billion, a price-to-earnings ratio of 3,125.20 and a beta of 1.01. The firm’s fifty day moving average price is $147.44 and its 200 day moving average price is $115.61.

In other news, SVP Michael P. Spears sold 4,153 shares of Insulet stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.12, for a total value of $606,836.36. Following the transaction, the senior vice president now owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shacey Petrovic sold 649 shares of Insulet stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $152.40, for a total transaction of $98,907.60. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its position in Insulet by 4.9% during the 2nd quarter. Janus Henderson Group PLC now owns 369,611 shares of the medical instruments supplier’s stock worth $44,124,000 after purchasing an additional 17,328 shares during the last quarter. Jennison Associates LLC grew its position in Insulet by 53.6% during the 2nd quarter. Jennison Associates LLC now owns 283,817 shares of the medical instruments supplier’s stock worth $33,882,000 after purchasing an additional 98,995 shares during the last quarter. Swiss National Bank grew its position in Insulet by 2.4% during the 2nd quarter. Swiss National Bank now owns 110,300 shares of the medical instruments supplier’s stock worth $13,168,000 after purchasing an additional 2,600 shares during the last quarter. Columbus Circle Investors grew its position in Insulet by 74.6% during the 2nd quarter. Columbus Circle Investors now owns 165,863 shares of the medical instruments supplier’s stock worth $19,801,000 after purchasing an additional 70,860 shares during the last quarter. Finally, First Hawaiian Bank grew its position in Insulet by 2,758.3% during the 2nd quarter. First Hawaiian Bank now owns 1,715 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 1,655 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Recommended Story: Depreciation

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.